Video

Identifying Transplant Candidates in ALL

For High-Definition, Click

Objective parameters, such as performance status and comorbidity score, may be used to determine the eligibility of adult patients who have acute leukemia for stem cell transplant. Mark R. Litzow, MD, states that he considers any patient with high-risk, Philadelphia chromosome negative [Ph(-)] acute lymphoblastic leukemia (ALL) to be a candidate for transplant. Litzow comments that it is becoming increasingly difficult to determine the best candidate for transplant, but that it is still important to consider comorbidities, disease status, and donor availability.

Dan Douer, MD, notes that most clinical studies have demonstrated that allogeneic transplants are superior to autologous transplants in ALL; in fact, autologous transplants are not considered in this disease state. Jeffrey Lancet, MD, states that beyond first remission, allogeneic transplant offers the only realistic chance of cure and should be considered in this particular setting.

Related Videos
Craig Eckfeldt, MD, PhD, assistant professor, medicine, faculty, Microbiology, Immunology, and Cancer Biology PhD Graduate Program, Division of Hematology, Oncology, and Transplantation, the University of Minnesota Medical School
Mark Juckett, MD, professor, medicine, Division of Hematology, Oncology, and Transplantation, the University of Minnesota Medical School
Timothy Hughes, MD, MBBS, FRACP, FRCPA
Hannah Choe, MD, an expert on GVHD
Hannah Choe, MD, an expert on GVHD
Grzegorz S. Nowakowski, MD
Combination of Zanubrutinib + Venetoclax for Treatment-naive CLL/SLL With del(17p) and/or TP53: Preliminary Results From SEQUOIA Arm D
Preliminary Efficacy and Safety of the Bruton Tyrosine Kinase Degrader BGB-16673 in Patients With Relapsed or Refractory CLL/SLL: Results From the Phase 1 BGB-16673-101 Study
Results from the randomized phase 3 DREAMM-8 study of belantamab mafodotin plus pomalidomide and dexamethasone (BPd) vs pomalidomide plus bortezomib and dexamethasone (PVd) in relapsed/refractory multiple myeloma (RRMM)
Hannah Choe, MD, an expert on GVHD